Evidence map›Paper›PMID 39297702›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2024

LncRNA SLNCR1 facilitates angiogenesis and tumor growth in melanoma via DNMT1-mediated epigenetically silencing SPRY2.

Ke Li, Lijun Wu, Jingting Jiang

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. LncRNA SLNCR1 facilitates angiogenesis and tumor growth in melanoma via DNMT1-mediated epigenetically silencing SPRY2.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ke LiDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, Soochow University, Changzhou, Jiangsu, P. R. China.
Lijun WuDepartment of Plastic and Aesthetic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P. R. China.
Jingting JiangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, Soochow University, Changzhou, Jiangsu, P. R. China.

Funding

CNNC Elite Talent ProgramConstruction of key clinical specialties for the Suzhou Municipal "Strengthening Health through Science and Education" Funding ProjectHospital Research Fund SDFEYBS1805Hospital Research Fund SDFEYGJ2013Hospital Research Fund XKTJ-HRC20210015Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University GZK1202244Suzhou People's Livelihood Science and Technology Project SYS2020105Suzhou Science and Technology Development Project 2022SS43Suzhou Science and Technology Development Project SKJY2021078Suzhou Science and Technology Development Project SYS2020105the Special Project of "Technological Innovation" Project of CNNC Medical Industry Co. Ltd ZHYLZD2021002
6 · The paper itself

Abstract

backgroundThe malignancy of melanoma is attributed to its pronounced invasiveness, extensive vascularization, and rapid tumor cell growth and metastasis. LncRNA SLNCR1 is closely associated with a variety of aggressive tumors. However, our understanding of SLNCR1 influences on malignant melanoma growth metastasis mechanism especially proangiogenic mechanism remains unclear.

methodsThe expression of SLNCR1 was evaluated in melanoma tissues, adjacent tissues, melanoma cell lines. The abilities of SLNCR1 on proliferation, migration, and angiogenesis of HUVECs were detected by CCK-8, flow cytometry, and Western blot assays. The association between SLNCR1, DNMT1, and SPRY2 was assessed by ChIP, RIP, and Western blot assays. The effect of SLNCR1 on tumor growth was determined using a xenograft model in nude mice.

resultsSLNCR1 was confirmed to be highly expressed in melanoma tissues and cells. CM from melanoma cells transfected with sh-SLNCR1 attenuated proliferation, migration, and angiogenesis of HUVECs. Moreover, loss of SLNCR1 hindered tumor growth and metastasis, as evidenced by reduced tumor size and weight, as well as angiogenesis. Mechanistic studies revealed that SLNCR1 silenced SPRY2 expression, likely through enhancing DNMT1-mediated DNA methylation of SPRY2 promoter.

conclusionSLNCR1 is an oncogene that interacts with DNMT1 to mediate SPRY2 methylation, thereby suppressing SPRY2 expression and promoting the angiogenesis and tumor growth in melanoma. SLNCR1 may serve as a potential target for melanoma treatment.

Indexed as

Cell ProliferationDNA (Cytosine-5-)-Methyltransferase 1Intracellular Signaling Peptides and ProteinsMelanomaMembrane ProteinsMice, NudeNeovascularization, PathologicRNA, Long NoncodingSkin NeoplasmsAngiogenesisAnimalsCell Line, TumorCell MovementEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsRNA, Long NoncodingSPRY2 protein, humanangiogenesisDNMT1lncRNA SLNCR1melanomaSPRY2

Identifiers

PMID39297702
PMCPMC11411697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.